Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Ibuprofen + diphenhydramine hydrochloride** is a fixed-dose combination of two active pharmaceutical ingredients: ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties, and diphenhydramine hydrochloride, a first-generation antihistamine with sedative properties. The combination is primarily indicated as an over-the-counter nighttime pain reliever and sleep aid for the relief of minor aches and pains when they cause occasional insomnia. **Ibuprofen** acts mainly by reversible inhibition of cyclooxygenase (COX-1 and COX-2) enzymes, reducing the synthesis of prostaglandins involved in pain, fever, and inflammation. **Diphenhydramine hydrochloride** antagonizes histamine H1 receptors in the central nervous system, producing sedative and hypnotic effects, and also possesses anticholinergic activity. The product is formulated as oral capsules or liquid gels, commonly containing 200 mg ibuprofen with 25 mg diphenhydramine hydrochloride per unit dose[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + diphenhydramine hydrochloride.